CLINICAL TRIALS PROFILE FOR RISPERIDONE
✉ Email this page to a colleague
505(b)(2) Clinical Trials for risperidone
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| New Indication | NCT01770600 ↗ | Impulsivity and Thought Process Disorder in Patients With Active Suicidal Ideation and Depression | Withdrawn | University of Alabama at Birmingham | N/A | 2010-04-01 | This study is dedicated to achieving a better understanding of how the brain processes information. Specifically, the investigators are studying cognitive function, thought process, and impulsivity in people with and without suicidal thoughts. You are being asked to participate in a research study to learn how the use of a medication, risperidone, improves your symptoms of depression. Specifically the investigators are studying the effectiveness of reducing the thought of suicide and other symptoms of severe depression. Risperidone is approved by FDA for the treatment of schizophrenia and bipolar mania, and clinical practice suggests that it might benefit patients with major depressive disorder. During clinical trials with 2607 patients, risperidone was proved to be safe. This is a pilot study to test a new indication of risperidone for treatment of severe depression. The study medication will be given in addition to usual psychiatric care. |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for risperidone
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00000267 ↗ | Risperidone Treatment in Dually-Diagnosed Individuals - 2 | Completed | New York State Psychiatric Institute | Phase 2 | 1969-12-31 | The purpose of this study is to evaluate the safety and efficacy of risperidone for cocaine dependence in individuals with schizophrenia/schizoaffective illness. |
| NCT00000267 ↗ | Risperidone Treatment in Dually-Diagnosed Individuals - 2 | Completed | National Institute on Drug Abuse (NIDA) | Phase 2 | 1969-12-31 | The purpose of this study is to evaluate the safety and efficacy of risperidone for cocaine dependence in individuals with schizophrenia/schizoaffective illness. |
| NCT00000272 ↗ | Early Phase II Trials for Cocaine Medication Development - 1 | Completed | National Institute on Drug Abuse (NIDA) | Phase 2 | 1996-08-01 | The purpose of this study is to develop models for early Phase II testing of potential medications for cocaine dependence: amoxapine, risperidone and other agents. The study was a controlled pilot trial of risperidone in opiate-dependent patients on methadone maintenance. The study explored whether risperidone reduced cocaine use, cocaine craving, and cocaine subjective effects in patients on methadone maintenance who abused cocaine and whether it had an acceptable side effect profile. This |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for risperidone
Condition Name
Clinical Trial Locations for risperidone
Trials by Country
Clinical Trial Progress for risperidone
Clinical Trial Phase
Clinical Trial Sponsors for risperidone
Sponsor Name
